Press Releases

Home » Press Releases » Page 2
  • Psyence Clinical Trials

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

2022-09-19T13:05:24+02:00September 19, 2022|Press Releases, Investor Information|

Psyence has partnered with a leading psychedelic Contract Research Organisation (CRO), Clerkenwell Health, to design and deliver the clinical trial. Clerkenwell has experience in conducting psychedelic research and the trial will be conducted at two centers in the United Kingdom.

  • PSYENCE GROUP ANNOUNCES DTC ELIGIBILITY APPROVAL IN THE U.S.

Psyence Group Announces DTC Eligibility Approval in the U.S

2022-02-09T12:56:58+02:00February 9, 2022|Press Releases|

TORONTO, 09 February 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States (“US”).

  • PSYENCE_UPDATE_FEATURE

Psyence looks to expand capital market opportunities in the UK and Europe

2022-01-21T16:03:46+02:00January 21, 2022|Press Releases|

TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.

Go to Top